Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR vs. Surgery in Acromegaly
NCT00001860Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Aug 1999
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of octreotide in acromegaly (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Normalization of insulin-like growth factor-1 levels. Started Aug 1999; status: completed.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00001860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001860.